Drugs that contain Selinexor
1. Drug name - XPOVIO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9714226 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(9 years from now) | |
| US8999996 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Sep, 2032
(9 years from now) | |
| US10519139 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(12 years from now) | |
| CN106083827A | KARYOPHARM THERAPS | Transport Regulator And Use Thereof Containing A Hydrazide |
Jul, 2032
(9 years from now) | |
| CN103874690A | KARYOPHARM THERAPS | Transport Regulator And Use Thereof Containing A Hydrazide |
Jul, 2032
(9 years from now) | |
| CN103874690B | KARYOPHARM THERAPS | Transport Regulator And Use Thereof Containing A Hydrazide |
Jul, 2032
(9 years from now) | |
| CN103842340A | KARYOPHARM THERAPS | Nuclear Transport Modulatiors And Uses Thereof |
Jul, 2032
(9 years from now) | |
| CN106083827B | KARYOPHARM THERAPS | Nuclear Transport Modulators And Use Of Hydrazide-Containing |
Jul, 2032
(9 years from now) | |
| CN103842340B | KARYOPHARM THERAPS | Nuclear Transport Modulatiors And Uses Thereof |
Jul, 2032
(9 years from now) | |
| CN107072992A | KARYOPHARM THERAPS | Polymorph |
Aug, 2035
(12 years from now) | |
| CN107072992B | KARYOPHARM THERAPS | Polymorphs Of |
Aug, 2035
(12 years from now) | |
| IN201401189P1 | KARYOPHARM THERAPS | Hydrazide Containing Nuclear Transport Modulators And Uses Thereof |
Jul, 2032
(9 years from now) | |
| IN361872B | KARYOPHARM THERAPS | Hydrazide Containing Nuclear Transport Modulators And Uses Thereof |
Jul, 2032
(9 years from now) | |
| EP2736883B1 | KARYOPHARM THERAPS | Nuclear Transport Modulators And Uses Thereof |
Jul, 2032
(9 years from now) | |
| EP2736883A1 | KARYOPHARM THERAPS | Nuclear Transport Modulators And Uses Thereof |
Jul, 2032
(9 years from now) | |
| EP2736887B1 | KARYOPHARM THERAPS | Hydrazide Containing Nuclear Transport Modulators And Uses Thereof |
Jul, 2032
(9 years from now) | |
| EP2736887A1 | KARYOPHARM THERAPS | Hydrazide Containing Nuclear Transport Modulators And Uses Thereof |
Jul, 2032
(9 years from now) | |
| EP3180331A1 | KARYOPHARM THERAPS | Polymorphs Of Selinexor |
Aug, 2035
(12 years from now) | |
| EP3180331B1 | KARYOPHARM THERAPS | Polymorphs Of Selinexor |
Aug, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9079865 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(9 years from now) | |
| US10544108 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(9 years from now) | |
| US11034660 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(9 years from now) | |
Treatment: Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; xpovio is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl), not otherwise specified, including dlbcl arising from follicular lymphoma, after at least 2 lines of systemic therapy; xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 20MG | TABLET;ORAL | Prescription |
| 40MG | TABLET;ORAL | Prescription |
| 50MG | TABLET;ORAL | Prescription |
| 60MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.